Search results
Showing 8626 to 8640 of 8990 results
In development Reference number: GID-TA11104 Expected publication date: TBC
Discontinued Reference number: GID-TA10332
Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]
Discontinued Reference number: GID-TAG363
Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1178]
Discontinued Reference number: GID-TA10199
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
In development Reference number: GID-HST10037 Expected publication date: TBC
Farco-fill Protect for indwelling urinary catheterisation (MIB121)
July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.
This guidance has been replaced by NICE guideline NG17.
More than 20,000 people benefitting from innovative migraine pills recommended by NICE
A new type of tablet specifically designed to prevent migraine is transforming lives across England, with the number of people being prescribed these medicines more than tripling in just one year.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
Improving supportive and palliative care for adults with cancer (CSG4)
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
NICE publishes first quality standard to improve care for people with rare diseases
Ahead of Rare Disease Day on 28 February, we've published our first ever quality standard on rare diseases, and the first to have been developed in partnership with an external organisation.
How a collaborative taskforce is helping increase the uptake of biosimilars within the health and care sector.
Nice has recommended the first disease modifying treatment for arginase 1 deficiency (ARG1-D), an ultra-rare, inherited and progressive metabolic disorder, for routine use in the NHS in England.
How NICE guidance is accelerating access to innovative migraine treatments
Home News Podcasts How NICE guidance is accelerating access to innovative migraine treatments Podcasts 26 February 2026 Listen About this